Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Staccato Loxapine for Inhalation in Subjects on Chronic, Stable Antipsychotic Regimens

Trial Profile

Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Staccato Loxapine for Inhalation in Subjects on Chronic, Stable Antipsychotic Regimens

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Loxapine (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Alexza Pharmaceuticals
  • Most Recent Events

    • 27 May 2010 Results of this and another phase I loxapine safety trial (700043576) will be presented at the 163rd Annual Scientific Sessions of the American Psychiatric Association, according to an Alexza Pharmaceuticals media release.
    • 26 May 2010 Tolerability results, with respect to the incidence of cardiovascular adverse events, presented at the 163rd Annual Meeting of the American Psychiatric Association.
    • 08 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top